

Curriculum vitae  
**Candida Vitale, MD, PhD**

**Personal data**

Place of birth: Torino, Italy

Citizenship: Italian

**Current position:** Assistant Professor – Ricercatore a Tempo Determinato di tipo A, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy

**Work address:** S.C. Ematologia Universitaria, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3, 10126, Torino

Tel. +39 3471551761

E-mail: candida.vitale@unito.it

**Personal statement**

I am a physician scientist with a broad background in Hematology. I have a solid experience in translational and clinical research projects, and in the clinical management of patients with chronic lymphocytic leukemia. My interest for translational research in hematology dates back to the years of the Medical School, and since then I gained technical experience in cell biology, cell culture, cytofluorimetric analysis and molecular biology, as well as in the conduction of research projects exploring the interactions between the neoplastic clone, the tumor microenvironment and the immune system in the setting of lymphoproliferative diseases.

**Work experience**

<b>March 2020 – present</b>	Ricercatore a Tempo Determinato - Assistant Professor, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
<b>January 2019 – February 2020</b>	Fellowship "Fondazione Pezcoller - Ferruccio ed Elena Bernardi" in collaboration with SIC (Società Italiana di Cancerologia), University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
<b>September 2017- February 2020</b>	Collaboration with FO.NE.SA. (Fondazione Neoplasie Sangue) Onlus for clinical management and implementation of clinical studies and experimental therapies for patients with chronic lymphocytic leukemia, University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Italy
<b>September 2017 – August 2018</b>	Research Fellowship, Hematology Section, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
<b>August 2015 – August 2017</b>	Fellowship AIL ( <i>Associazione Italiana contro le Leucemie</i> ) for Hematology Specialist, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
<b>July 2014 – July 2015</b>	Leukemia Fellowship Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
<b>July 2009 – July 2014</b>	Residency/Fellowship in Hematology, University of Torino, Italy (Prof. Massimo Massaia – Dr. Marta Coscia)
<b>March 2007 - June 2009</b>	Internship, Laboratory of Hematological Oncology (CeRMS) and University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy (Prof. Massimo Massaia – Dr. Marta Coscia)
<b>March 2003 - October 2005</b>	Internship, Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino, Italy (Prof. Fabio Malavasi)

### Education and training

<b>September 2018 – October 2018</b>	<i>Observership</i> , Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
<b>December 2012 – January 2017</b>	PhD School in Molecular Medicine, University of Torino, Italy
<b>November 2016 – June 2017</b>	EHA (European Hematology Association) Clinical Research Training in Hematology
<b>July 2014 – July 2015</b>	<i>Leukemia Fellowship Program</i> , Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
<b>August 2013 – Septembre 2013</b>	<i>Observership</i> , Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
<b>July/September 2013</b>	United States Medical Licensing Examination – STEP 1 (score 220), STEP 2 CK (score 241), STEP 2 CS
<b>July 2009 – July 2014</b>	Postgraduate School in Hematology, University of Torino, Italy
<b>February 2009</b>	Italian Board Examination for MD
<b>2002 - 2008</b>	School of Medicine, University of Torino, Italy (110/110 cum laude)
<b>1997 - 2002</b>	High School Liceo Classico Massimo D'Azeglio, Torino, Italy (100/100)

### Technical skills and competences

Inward and outpatient care of neoplastic and non-neoplastic hematological patients, with a special interest in management and record of chronic lymphocytic leukemia patients. Co-investigator in national and international phase II and III Clinical Trials. Well acquainted with Good Clinical Practice for clinical trials.

Good experience in cell biology, cell culture, cytofluorimetric analysis (immunophenotypic characterization of different cell populations, cytotoxic assay, apoptosis); experience in molecular biology.

### Scientific interests

Biology and treatment of hematological malignancies, with a special focus on chronic lymphocytic leukemia. Prospective and observational studies in chronic lymphocytic leukemia. Interactions between the neoplastic clone, tumor microenvironment and immune system, and mechanisms of drug resistance. Tumor-related immune dysfunctions and immunomodulatory properties of new targeted drugs in chronic lymphocytic leukemia. Immunotherapy strategies for patients with hematologic malignancies.

### Clinical and research activity

Regular inpatient and outpatient clinical activity within the University Division of Hematology, Città della Salute e della Scienza University Hospital of Torino, Italy. Investigator in >30 clinical trials investigating the role of new drugs for the treatment of patients with chronic lymphocytic leukemia and non-Hodgkin lymphomas.

### Teaching activity

Lecturer in the Master Program II level - Stem cells in Regenerative Medicine and Cell Factory Management (Modules on CAR T-cell therapy), University of Torino, Italy (2020-present)  
Lecturer in the Post-graduate School of Hematology, University of Torino, Italy (2020-present)  
Lecturer in the School of Medicine, University of Torino, Italy (2020-present)

### Editorial activity

Expert reviewer of abstracts submitted under the topic "Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research", for the EHA2022 Congress.

Peer reviewer for Frontiers in Oncology, Cancer Immunology, Immunotherapy, Therapeutic Advances in Hematology. Member of the "Reviewer Board" for Cancers.

### Membership of scientific societies

- European Hematology Association (EHA)
- Società Italiana di Ematologia (SIE)
- European Research Initiative on CLL (ERIC)
- Membro della European Association for Cancer Research (EACR)
- Society of Hematologic Oncology (SOHO)
- Società Italiana di Cancerologia (SIC)
- FIL (Fondazione Italiana Linfomi)

### Awards and honors

- Winner of the award given by *Fondazione Federico Calabresi*, selected by *Comitato Scientifico di Grandangolo in Ematologia 2022*, for the best hematology publication on a high impact factor international journal as a first Author younger than 40
- IWCLL (International Workshop on Chronic Lymphocytic Leukemia) *Young Investigator travel scholarship award* 2019, XVII IWCLL Meeting, Edinburgh, September 20-23 2019
- SOHO (Society of Hematologic Oncology) 2019 *Young Investigator Travel Grant*, 2019 SOHO Annual Meeting, Houston, TX, USA, September 11-14 2019
- 2016-2017 European Hematology Association Clinical Research Training in Hematology (EHA CRTH) participant
- Celgene 2016 Future Leaders Award for Clinical Research in Hematology
- SOHO (Society of Hematologic Oncology) 2016 *Young Investigator Travel Grant*, 2016 SOHO Annual Meeting, Houston, TX, USA. September 6-10 2016.
- Best Clinical Fellow for the 2014-2015 Leukemia Fellowship Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
- American Society of Hematology Abstract Achievement Award, 56th American Society of Hematology Meeting, December 5-9, 2014, San Francisco, CA, USA
- Travel Grant, 5th International gamma delta T-cell conference, May 31-June 5 2012, Freiburg, Germany.

### Peer-reviewed publications

- Salveti C, Vitale C, Griggio V, Drandi D, Jones R, Bonello L, Bomben R, Bragioni A, Bagnara D, Fais F, Gattei V, Cavallo F, Zamò A, Coscia M. Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. *Front Oncol*. 2022 Jun 6;12:917115.
- Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R, Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti L. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. *Blood Adv*. 2022 Jul 12;6(13):3875-3878.
- Marchetti M, Vitale C, Rigolin GM, Vasile A, Visentin A, Scarfò L, Coscia M, Cuneo A. Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. *J Clin Med*. 2022 Apr 7;11(8):2076.
- Deodato M, Frustaci AM, Sportoletti P, Laurenti L, Murru R, Visentin A, Reda G, Mauro FR, Quaresmini G, Vanazzi A, Vitale C, Orsucci L, Massaia M, Sanna A, Motta M, Ibatìci A, Ferrarini I, Borella C, Varettoni M, Tani M, Marinoni S, Ferrario A, Zamprognà G, Montillo M, Tedeschi A. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2022 Mar 27;1-4. doi: 10.1080/10428194.2022.2053532. Epub ahead of print.
- Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Piazza F, Coscia M, Laurenti L, Molica S, Foà R, Cuneo

A, Trentin L. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. *Am J Hematol.* 2022 Mar 1;97(3):E95-E99.

-Perutelli F, Jones R, Griggio V, Vitale C\*, Coscia M\*. Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges. *Frontiers in Oncology.* Online ahead of print. 2022 Feb 21. \*equally contributing senior authors

-Molica S, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Moia R, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Deodato M, Ielo C, Noto A, Guarente V, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foà R, Trentin L, Mauro FR. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. *Am J Hematol.* 2022 May;97(5):E176-E180.

-Vitale C, Gibbons JL, Ferrajoli A. Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib. *Onco Targets Ther.* 2021 Dec 29;14:5507-5519.

- Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efsthropoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghunyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gelder M, van Kampen R, Varettoni M, Visentin A, Vitale C, Wasik-Szczepanek E, Wróbel T, San Segundo LY, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Stamatopoulos K, Ghia P. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. *Leukemia.* 2021 Dec;35(12):3444-3454.

- Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamproga G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? *Blood Adv.* 2021 Dec 28;5(24):5490-5500.

- D'Arena G, Vitale C, Coscia M, Lamorte D, Pietrantonio G, Perutelli F, D'Auria F, Statuto T, Valvano L, Tomasso A, Griggio V, Jones R, Mansueto G, Villani O, D'Agostino S, Viglioglia V, De Feo V, Calapai F, Mannucci C, Sgambato A, Efremov DG, Laurenti L. CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. *Cancers (Basel).* 2021 Aug 23;13(16):4239.

- Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V, Coscia M. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. *Cancers (Basel).* 2021 Jul 30;13(15):3856.

- Mauro FR, Giannarelli D, Visentin A, Reda G, Sportoletti P, Frustaci AM, Chiarenza A, Ciolli S, Vitale C, Laurenti L, De Paoli L, Murru R, Gentile M, Rigolin GM, Levato L, Giordano A, Del Poeta G, Stelitano C, Ielo C, Noto A, Guarente V, Molica S, Coscia M, Tedeschi A, Gaidano G, Cuneo A, Foà R, Martelli M, Girmenia C, Gentile G, Trentin L. Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. *Cancers (Basel).* 2021 Jun 29;13(13):3240.

- Vitale C, Salvetti C, Griggio V, Porrazzo M, Schiattone L, Zamproga G, Visentin A, Vassallo F, Cassin R, Rigolin GM, Murru R, Laurenti L, Rivela P, Marchetti M, Pennese E, Gentile M, Boccellato E, Perutelli F, Montalbano MC, De Paoli L, Reda G, Orsucci L, Trentin L, Cuneo A, Tedeschi A, Scarfò L, Gaidano G, Mauro FR, Foà R, Boccadoro M, Coscia M. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. *Blood.* 2021 Jun 24;137(25):3507-3517.

- Vitale C, Griggio V, Riganti C, Todaro M, Kopecka J, Jones R, Salvetti C, Boccellato E, Perutelli F, Voena C, Godio L, Boccadoro M, Coscia M. Targeting HIF-1 $\alpha$  Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. *Cancers (Basel).* 2021 Jun 9;13(12):2883.

- Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale C,

Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD. B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide. *Blood*. 2021 Apr 22;137(16):2267-2271.

- Dogliotti I, Ragaini S, Vassallo F, Boccellato E, De Luca G, Perutelli F, Boccomini C, Clerico M, Botto B, Grimaldi D, Orsucci L, Ferrero S, Vitale C, Ferrero D, Coscia M, Cavallo F. Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. *J Pers Med*. 2021 Mar 30;11(4):249.

- Mauro FR, Giannarelli D, Galluzzo CM, Vitale C, Visentin A, Riemma C, Rosati S, Porrazzo M, Pepe S, Coscia M, Trentin L, Gentile M, Raponi S, Micozzi A, Gentile G, Baroncelli S. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). *Leukemia*. 2021 Mar;35(3):737-746.

- Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C\*, Coscia M\*. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. *Front Immunol*. 2020 Nov 18;11:594556. *\*equally contributing senior authors*

- Gentile M, Martino EA, Visentin A, Coscia M, Reda G, Sportoletti P, Mauro FR, Laurenti L, Varettoni M, Murru R, Chiarenza A, Vigna E, Mendicino F, Lucia E, Bossio S, Recchia AG, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Al-Janazreh H, Vitale C, Tripepi G, D'Arrigo G, Angeletti I, Bomben R, Neri A, Cutrona G, Fronza G, Di Raimondo F, Gaidano G, Cuneo A, Foà R, Ferrarini M, Trentin L, Gattei V, Morabito F. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. *Blood Cancer J*. 2020 Sep 16;10(9):92.

- Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrengeha M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. *Leukemia*. 2020 Sep;34(9):2354-2363.

- Vitale C, Ferrajoli A. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. *Expert Rev Hematol*. 2020 Aug;13(8):885-894.

- Porrazzo M, Nicolai E, Riminucci M, Vitale C, Coscia M, De Paoli L, Rago A, Buscicchio G, Maestrini G, Ligia S, Di Prima A, Corsi A, Caronna R, Gaidano G, Mauro FR. Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. *Cancers (Basel)*. 2020 Jul 3;12(7).

- Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. *Front Oncol*. 2020 May 27;10:849.

- Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. *Front Immunol*. 2020 May 12;11:888.

- Griggio V\*, Vitale C\*, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Bo MD, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M. HIF-1 $\alpha$  is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. *Haematologica*. 2020 Apr;105(4):1042-1054. *\*equally contributing authors*

- Vitale C, Montalbano MC, Salvetti C, Boccellato E, Griggio V, Boccadoro M, Coscia M. Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. *Cancers (Basel)*. 2020 Jan 23;12(2).

- Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. *J Geriatr Oncol*. 2020 Jan;11(1):19-23.

- Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L. A scoring system to predict the risk of



atrial fibrillation in chronic lymphocytic leukemia. *Hematol Oncol*. 2019 Oct;37(4):508-512.

- D'Arena G, Valvano L, Vitale C, Coscia M, Statuto T, Bellesi S, Lamorte D, Musto P, Laurenti L, D'Auria F. CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. *Leuk Res*. 2019 Aug;83:106169.

- Coscia M\*, Vitale C\*, Cerrano M, Maffini E, Giaccone L, Boccadoro M, Bruno B. Adoptive immunotherapy with CARs modified T cells in cancer: current landscape and future perspectives. *Front Biosci (Landmark Ed)*. 2019 Jun 1;24:1284-1315. *\*equally contributing authors*

- Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. *Cancers (Basel)*. 2019 Jun 26;11(7).

- Vitale C, Ferrajoli A. Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia. *Haematologica*. 2019 Jan;104(1):9-12.

- D'Arena G, Vitale C, Coscia M, D'Auria F, Bellesi S, Topini G, Panichi V, Valvano L, Statuto T, Corrente F, Laurenti L. External validation of the accuracy of 'CLLflow score'. *J Investig Med*. 2018 Oct;66(7):e6.

- D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L. CD200 included in a 4-marker modified Matutes Score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukemia. *Hematol Oncol*. 2018 Mar 30.

- Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Ferrajoli A, Futreal PA, Wierda WG. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. *Blood*. 2018 Jan 22.

- D'Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M, Calapai G, Laurenti L, Musto P, Di Minno G, Fenoglio D. Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. *J Immunol Res*. 2017;2017:1832968.

- D'Arena G, Vitale C, Perbellini O, Coscia M, La Rocca F, Ruggieri V, Visco C, Di Minno NMD, Innocenti I, Pizza V, Deaglio S, Di Minno G, Giudice A, Calapai G, Musto P, Laurenti L, Iorio EL. Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. *Eur J Haematol*. 2017 Oct;99(4):306-314.

- Vitale C, Griggio V, Todaro M, Salvetti C, Boccadoro M, Coscia M. Magic pills: new oral drugs to treat chronic lymphocytic leukemia. *Expert Opin Pharmacother*. 2017 Mar;18(4):411-425.

- Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, Drandi D, Omedè P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. *Oncotarget*. 2017 Jan 10;8(2):3274-3288.

- Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. *Haematologica*. 2016 Jun;101(6):e254-8.

- Vitale C, Burger JA. Chronic lymphocytic leukemia therapy: new targeted therapies on the way. *Expert Opin Pharmacother*. 2016 Jun;17(8):1077-89.

- Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbitto KY, Strom S, Wierda WG, Ferrajoli A. Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia. *Ann Oncol*. 2016 Jun;27(6):1100-6.

- Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. *Am J Hematol*. 2016 Jun;91(4):E274-6.

- Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin GA, O'Brien S, Faderl S, Wang X, Wierda W, Rezvani K, Reuben JM, Burger J, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation Between Responses and Immune Characteristics. *Clin Cancer Res*. 2016 May 15;22(10):2359-67.

- Vitale C, Ferrajoli A. Richter Syndrome in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2016 Feb;11(1):43-51.
- Vitale C, Lu X, Abderrahman B, Takahashi K, Ravandi F, Jabbour E. t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia. Am J Hematol. 2015 Nov;90(11):E211-2.
- Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget. 2015 Oct 6;6(30):29833-46.
- Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omedè P, Riganti C, Palumbo A, Boccadoro M, Massaia M. Anergic bone marrow Vgamma9Vdelta2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. Oncoimmunology. 2015 May 26;4(11):e1047580.
- Alattar ML\*, Ciccone M\*, Gaballa MR\*, Vitale C\*, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Apr 29;1-9. *\*equally contributing authors*
- Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzzone S, Deaglio S. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia. 2015 Feb;29(2):356-68.
- Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Nov 20;1-3.
- Coscia M\*, Vitale C\*, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournié JJ, Massaia M. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood. 2012 Oct 18;120(16):3271-9. *\*equally contributing authors*
- Castella B\*, Vitale C\*, Coscia M, Massaia M. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci. 2011 Jul;68(14):2419-32. *\*equally contributing authors*
- Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia. 2011 May;25(5):828-37.
- Mariani S, Hwang SY, Foglietta M, Bonello L, Vitale C, Coscia M, Fiore F, Bruno B, Massaia M. Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. Exp Hematol. 2009 Jun;37(6):728-38.

Torino, 27th July 2022

Candida Vitale



Acconsento al trattamento dei miei dati personali ai sensi del d.lgs 196 del 30 giugno 2003.

